IN THE UNITED STATES PATENT AND TRADEMARK OFFICE e Patent Application of:

Docket No.: PF112U1

Application No.: 09/499,468-Conf. #1320

Allowed: December 30, 2004

Filed: February 7, 2000

derson et al.

Art Unit: 1647

For: Use of Vascular Endothelial Growth Factor To

Treat Photoreceptor Cells (as amended)

Examiner: R. Landsman

ISSUE FEE TRANSMITTAL LETTER

MS Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance and Fee(s) Due, mailed December 30, 2004 (Paper No. 12170), Applicants submit herewith:

- Part B Fee(s) Transmittal (PTOL-85), with appropriate fee(s) (in (a) duplicate);
- Response and Amendment Under 37 C.F.R. § 1.312; (b)
- Replacement Figures 2A and 2D (2 sheets); and (c)
- Statement Under 37 C.F.R. § 3.73, Revocation of Prior Powers of Attorney (d) or Authorizations of Agent, and Power of Attorney or Authorization of Agent.

The U.S. Patent and Trademark Office is hereby authorized to charge any deficiency in the fees filed, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: Uauch 14,2005

Respectfully submitted,

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road Rockville, Maryland 20850

(301) 610-5764